HUTCHMED (China): Oncology sales surged over 40% in China, global launches expanded, and cash reserves remained strongQuartr·3 hours agoHCM-6.41%00013-6.00%
HUTCHMED H1 FY26 net income drops to USD 15.9 million; revenue rises 0.22% to USD 278.3 millionPUBT·4 hours agoHCM-6.41%00013-6.00%
STOCKS | Hutchmed (China) Says ORPATHYS Approved in China for MET-Amplified GC/GEJ CancerCoinLive·Jul 2 at 05:33 AM00013-6.00%HCM-6.41%
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification | HCM Stock NewsStockTitan·Jul 1 at 07:30 PMHCM-6.41%
HUTCHMED to Announce 2026 Half-Year Financial Results | HCM Stock NewsStockTitan·Jun 29 at 07:30 PM00013-6.00%HCM-6.41%
REG - Hutchmed China Ltd - Announcement on blocklisting six monthly returnLondon Stock Exchange·Jun 29 at 03:30 AMHCM-6.41%00013-6.00%
HUTCHMED's Experimental Drug Shows Durable Responses In Advanced Bile Duct Cancer Trialbenzinga_article·Jun 25 at 11:08 AM00013-6.00%HCM-6.41%
HUTCHMED’s Fanregratinib Delivers Strong Phase II Data in FGFR2-Positive CholangiocarcinomaTip Ranks·Jun 24 at 07:07 PMHCM-6.41%00013-6.00%
